Cellectar Biosciences Stock Probability of Future Stock Price Finishing Over 4.41
CLRB Stock | USD 1.54 0.01 0.65% |
Cellectar |
Cellectar Biosciences Target Price Odds to finish over 4.41
The tendency of Cellectar Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current Price | Horizon | Target Price | Odds to move over $ 4.41 or more in 90 days |
1.54 | 90 days | 4.41 | close to zero percent |
Based on a normal probability distribution, the odds of Cellectar Biosciences to move over $ 4.41 or more in 90 days from now is close to zero percent (This Cellectar Biosciences probability density function shows the probability of Cellectar Stock to fall within a particular range of prices over 90 days) . Probability of Cellectar Biosciences price to stay between its current price of $ 1.54 and $ 4.41 at the end of the 90-day period is close to 99 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.13 suggesting Cellectar Biosciences market returns are sensitive to returns on the market. As the market goes up or down, Cellectar Biosciences is expected to follow. Additionally Cellectar Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Cellectar Biosciences Price Density |
Price |
Predictive Modules for Cellectar Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cellectar Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cellectar Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cellectar Biosciences is not an exception. The market had few large corrections towards the Cellectar Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cellectar Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cellectar Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.66 | |
β | Beta against Dow Jones | 1.13 | |
σ | Overall volatility | 0.18 | |
Ir | Information ratio | -0.25 |
Cellectar Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cellectar Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cellectar Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.Cellectar Biosciences generated a negative expected return over the last 90 days | |
Cellectar Biosciences may become a speculative penny stock | |
Net Loss for the year was (37.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Cellectar Biosciences currently holds about 24.81 M in cash with (32.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Cellectar Biosciences has a poor financial position based on the latest SEC disclosures | |
Latest headline from insidermonkey.com: Cellectar Biosciences, Inc. Q3 2024 Earnings Call Transcript |
Cellectar Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cellectar Stock often depends not only on the future outlook of the current and potential Cellectar Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cellectar Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 12.2 M | |
Cash And Short Term Investments | 9.6 M |
Cellectar Biosciences Technical Analysis
Cellectar Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Cellectar Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cellectar Biosciences. In general, you should focus on analyzing Cellectar Stock price patterns and their correlations with different microeconomic environments and drivers.
Cellectar Biosciences Predictive Forecast Models
Cellectar Biosciences' time-series forecasting models is one of many Cellectar Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cellectar Biosciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cellectar Biosciences
Checking the ongoing alerts about Cellectar Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cellectar Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Cellectar Biosciences generated a negative expected return over the last 90 days | |
Cellectar Biosciences may become a speculative penny stock | |
Net Loss for the year was (37.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Cellectar Biosciences currently holds about 24.81 M in cash with (32.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Cellectar Biosciences has a poor financial position based on the latest SEC disclosures | |
Latest headline from insidermonkey.com: Cellectar Biosciences, Inc. Q3 2024 Earnings Call Transcript |
Check out Cellectar Biosciences Backtesting, Cellectar Biosciences Valuation, Cellectar Biosciences Correlation, Cellectar Biosciences Hype Analysis, Cellectar Biosciences Volatility, Cellectar Biosciences History as well as Cellectar Biosciences Performance. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.